Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
September 1, 2025: FDA Approves Wegovy for Fatty Liver Disease The FDA has granted a new indication for Wegovy (semaglutide) to treat metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease in adults with moderate to advanced fibrosis
This is unless you order the single dose pen version of 7.2mg
Patients with chronic kidney disease (particularly non-dialysis CKD), liver conditions, or other metabolic disorders should consult their healthcare team before increasing protein intake, as individual requirements may differ substantially
Adapted from Wilding et al
US$ 28.40
US$ 27.47
US$ 25.30
US$ 27.71
